Big Pharma Leads Development Of Novel Antibody-Drug Conjugates
An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs.
An analysis of new ADCs in Phase III studies shows the difficulties, and possible rewards, of developing these drugs.